Chagin Karen Deborah 4

What Happened Karen Deborah Chagin, Chief Medical Officer of Context Therapeutics (CNTX), was granted a derivative award covering 290,000 shares on February 19, 2026. The filing reports an acquisition price of $0.00 (derivative instrument) — this was a grant of an option/award, not an open-market purchase or sale, so no cash changed hands and no shares were sold.

Key Details

• Transaction date: 2026-02-19; Form 4 filed: 2026-02-23 (timely filing).
• Instrument/amount: Grant/award (derivative) for 290,000 shares; acquisition price reported as $0.00.
• Vesting: 25% vests on Feb 19, 2027; remaining 75% vests in equal monthly installments over the next three years, subject to continued service (per footnote F1).
• Shares owned after transaction: not specified in the provided summary of the filing.
• No 10b5-1 plan, tax withholding, or cashless exercise reported in the provided information.

Context This was an equity award (option/derivative) with a multi-year vesting schedule — common for employee retention and long-term incentive plans. Because it’s a grant (not a purchase or sale), it doesn’t directly signal buying/selling intent and does not provide immediate liquidity. Monitor future Form 4s if/when options vest and are exercised or if any shares are sold.